Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
0.4100
-0.0006 (-0.15%)
At close: May 28, 2025, 4:00 PM
0.4000
-0.0100 (-2.44%)
After-hours: May 28, 2025, 6:55 PM EDT
Lyell Immunopharma Employees
Lyell Immunopharma had 300 employees as of December 31, 2024. The number of employees increased by 76 or 33.93% compared to the previous year.
Employees
300
Change (1Y)
76
Growth (1Y)
33.93%
Revenue / Employee
$217
Profits / Employee
-$1,115,073
Market Cap
121.09M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 300 | 76 | 33.93% |
Dec 31, 2023 | 224 | -50 | -18.25% |
Dec 31, 2022 | 274 | 55 | 25.11% |
Dec 31, 2021 | 219 | 29 | 15.26% |
Dec 31, 2020 | 190 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
LYEL News
- 15 days ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 - GlobeNewsWire
- 27 days ago - Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025 - GlobeNewsWire
- 6 weeks ago - Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma - GlobeNewsWire
- 2 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference - GlobeNewsWire
- 6 months ago - Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting - GlobeNewsWire
- 7 months ago - Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire